This technology utilizes Ethyl 3-methyl-3-phenylglycidate, an additive with proven safety, as an active ingredient in a composition that protects skin damaged by chemotherapy. By reducing the apoptosis of keratinocytes caused by anticancer drugs, it can be used in cosmetics, food products, quasi-drugs, and pharmaceutical compositions.
While surgery and radiation therapy focus on specific tumor sites, chemotherapy—where drugs circulate through the bloodstream—has been identified as a primary cause of widespread side effects in healthy tissues. As chemotherapy is widely used both alone and in combination with other treatments, there is a clear need for materials that can mitigate the resulting skin damage.
This technology leverages the principle that Ethyl 3-methyl-3-phenylglycidate protects epidermal cells by reducing keratinocyte apoptosis and LDH leakage triggered by anticancer drug exposure. It is effective against drugs such as 5-fluorouracil, doxorubicin, and docetaxel, covering treatments for colon, breast, ovarian, liver, and lung cancers. It can be applied to oncology-specific skincare, hospital-linked quasi-drugs, and ingestible skin-protective foods, transforming a common additive into a high-value skin protection material.
N/A
